In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk

The authors investigate whether the addition of dapirolizumab pegol to usual care can improve disease activity in patients with systemic lupus erythematosus (SLE) over a 48-week period. The findings indicate that dapirolizumab pegol significantly enhances disease activity compared to placebo, suggesting its potential as an effective treatment option for SLE.